UIAA Medical Advice: Emergency Field Management of ACS, HAPE and HACE

Acute mountain sickness (AMS), high altitude pulmonary edema (HAPE) and high altitude cerebral edema (HACE) are the most important and most common altitude-related diseases. Up to altitudes of about 5000-6000m, symptoms of altitude illness are a direct result of inadequate acclimatization.

The UIAA Medical Commission has produced a dedicated paper titled ‘Emergency Field Management of Acute Mountain Sickness, High Altitude Pulmonary Edema, and High Altitude Cerebral Edema’. The latest edition was published in 2012 and is available in Czech, English, German, Italian, Japanese, Persian, Polish, Russian and Spanish.

Dependent on the ascent profile, up to >70% of mountaineers may suffer from symptoms of AMS. Primary prevention is therefore considered the gold standard to avoid altitude illness. This includes a conservative ascent profile, adequate hydration and energy intake, and early recognition and management of potential medical problems, both before and during the trip.

This recommendation focuses on adult mountaineers (for children see UIAA Standard No. 9 and our dedicated article). In particular, the recommendation concentrates on situations where prevention has failed or other factors contributed to the development of AMS, HACE or HAPE (weather, rescue missions, medical predisposition etc).

Note 1: Since many trekking organizations do not follow an adequate altitude/time profiles prevention starts before booking! Check carefully the profile of your tour!

Note 2: An “adequate altitude/time profile” is defined in the paper.

Risk situations for AMS, HAPE, and HACE

Risk factors

Inadequate high altitude ascent profile (i.e., too rapid an ascent) and /or ignorance of the need for acclimatisation

g.: airport of destination at high altitude, ascent by vehicle or undertaking an “aggressive” altitude profile while hiking. Note: The high camps of several expedition routes are situated within ~1000m of altitude difference. Here “yo-yo” tactics” (no overnight stay for the first ascent(s) to these camps) is recommended.

Team blocked/stranded at high altitude

“Re-entry problems” of people living at high altitude after visiting sea level for several days or weeks

Previous History of AMS, HACE or HAPE

Victim ignoring early symptoms of altitude illness

Dehydration

Elderly people (>65 years) showed a 3-fold higher risk for HAPE. No such risk was found for AMS and HACE.

– Above 2500-3000m the next night should not be planned more than 300-500m higher than the previous one

– Have two nights at the same altitude after every 2-4 days of ascent. On this day you may climb higher, but return to sleep.

– The use of drugs to prevent altitude symptoms should be restricted to some special situations, especially if a fast ascent cannot be avoided for any reason (airport of destination at high altitude, rescue operations) or when a person suffers from symptoms although he/she has followed an adequate altitude profile (so called “slow acclimatiser”). For several reasons, especially cost-effectiveness-risk-ratios, acetazolamide is recommended. Mostly 500 mg/day has been recommended, but the dose-responsiveness is limited and 250-750 mg/day has been proven to be nearly equally effective.

Typical symptoms of AMS

Headache (most often diffuse and non-localized, but other types of headache do not exclude AMS)

Sleep disorders

Loss of appetite

Dizziness

Listlessness

Peripheral oedema

Severe heart palpitation

Nausea or vomiting

Note: AMS is a clinical diagnosis and should not be based strictly on any scoring system. Such systems may be used to quantify the severity of AMS.

Ataxia
o Note: The heel-to-toe walking test is a very sensitive and simple field test which also helps to differentiate unclear situations (e.g. if people want to mask their symptoms)

Altered consciousness, confusion or hallucinations
o Irrational behaviour may indicate an early stage!

Final stage: coma and death by respiratory paralysis

Frequently there is loss of insight, by the patient, who may insist that they are all right and just wish to be left alone.

Note: Lay persons should always treat mountaineers for AMS, HAPE, HACE first, unless they are absolutely sure that there is another reason for the symptoms. Doctors should also always consider AMS, HAPE, or HACE at (high) altitude first, but they should always take other diagnoses into account, especially those listed in the tables identified in the paper.

Note: If it should be impossible for lay persons to decide whether a patient suffers from HAPE or HACE he should be treated for both.

The full paper – including links to appendices and footnotes – can be downloaded here.

This is the latest extra from the UIAA’s internationally renowned high-altitude medical papers. To discover more please click here.

Contact

Navigation

For the Climbers. For the World.

Founded in 1932, the UIAA is the international federation for climbing and mountaineering. The UIAA represents the interests of over three million climbers and mountaineers from more than 90 member associations on all six continents. The UIAA has been recognised by the International Olympic Committee (IOC) since 1995.